Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysis

✍ Scribed by Faouzi Saliba; Sébastien Dharancy; Richard Lorho; Filoména Conti; Sylvie Radenne; Martine Neau-Cransac; Monika Hurtova; Jean Hardwigsen; Yvon Calmus; Jérome Dumortier

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 193 KB
• Volume: 17
• Category: Article
• ISSN: 1527-6465
• DOI: 10.1002/lt.22292

✦ Synopsis

Data on the conversion of patients to everolimus after liver transplantation are sparse. A multicenter, retrospective study followed 240 maintenance liver transplant patients to analyze the current indications for everolimus conversion, the employed regimens and exposure levels, and the impact on efficacy and safety. The mean time from transplantation to the introduction of everolimus was 4.9 6 5.2 years. The mean everolimus trough level was 7.3 6 4.1 ng/mL at month 1 and 8.1 6 4.7 ng/ mL at month 12. At 12 months, 61.6% of the patients were no longer receiving calcineurin inhibitor (CNI) therapy. The mean estimated glomerular filtration rate (eGFR) according to the Cockcroft-Gault formula was 64.2 6 30.0 mL/minute on day 0 and 68.4 6 32.5 mL/minute at month 12 (P ¼ 0.007). Among patients with baseline serum creatinine levels ! 130 lmol/L, the eGFR values were 44.3 6 15.7 mL/minute on day 0 and 53.7 6 26.0 mL/minute at month 12 (P ¼ 0.003). Four patients (1.6%) developed mild or moderate biopsy-proven acute rejection. Adverse events led to everolimus discontinuation in 12.9% of the patients. After the initiation of everolimus, the mean white blood cell count decreased significantly, and the total cholesterol and triglyceride levels increased significantly. In this retrospective analysis of the largest cohort of maintenance liver transplant patients analyzed after their conversion to everolimus, more than 60% of the patients were kept free of CNIs with a very low risk of acute rejection and with an acceptable safety profile. Randomized trials in which maintenance liver transplant patients are switched to everolimus in response to clinical indications or preemptively are warranted.